Navigation Links
Important Drug Product Notice: Luitpold Pharmaceuticals, Inc. Announces Temporary Suspension of Distribution and Manufacture of Drug Products
Date:4/21/2011

SHIRLEY, N.Y., April 21, 2011 /PRNewswire/ -- Luitpold Pharmaceuticals, Inc. ("Luitpold") today announced that it has temporarily suspended distribution of all of its drug products manufactured at its Shirley, New York facility and marketed by its American Regent, Inc. subsidiary and Animal Health Division.  This action DOES NOT affect products manufactured at its PharmaForce Inc. subsidiary, including its Betamethasone Sodium Phosphate and Betamethasone Sodium Acetate Injectable Suspension, USP. Osteohealth and Regency Therapeutics Division products, including SPRIX® (Ketorolac Tromethamine) Nasal Spray are not affected.

As a result of a recent inspection and a follow-up meeting with FDA on April 14, 2011, Luitpold agreed to temporarily suspend distribution of any drug product manufactured at its Shirley, New York facility.  (It had previously suspended the manufacture of its drug products on its own initiative).

Luitpold is in the process of developing a plan, in conjunction with outside consultants and the FDA, that will allow it to resume manufacturing and distribution of its drug products as soon as possible.  Luitpold Pharmaceuticals, Inc. will provide further information on its estimated timetable to resume supply of products to the market in the near future.

Luitpold has communicated with the FDA Drug Shortage Staff regarding this issue, and will work with them to address potential shortages of drug products critical to patient health.  

Any questions concerning this notice should be directed to the American Regent Customer Service Department at 1-800-645-1706 or the Animal Health Division at 1-800-458-0163.


'/>"/>
SOURCE Luitpold Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Important Drug Information Notice Regarding Sodium Thiosulfate Injection, USP, 10% (100mg/mL), 10mL Single Dose Vials and 25% (250mg/mL), 50mL Single Dose Vials
2. Important Drug Information Notice Regarding Potassium Phosphates Injection, USP, 3 mM/mL Phosphorous; 4. 4 mEq/mL Potassium: 5 mL, 15 mL and 50 mL Single Dose Vials
3. PNP Therapeutics Meets Important Financial and Regulatory Objectives in Development of New Cancer Therapies
4. Urgent: OTC DRUG Nationwide Recall--Important information for patients about IV PREP Antiseptic Wipes
5. ICAP Ocean Tomo Announces Four Patent Sets From Oxford Instruments - Each Represents an Important Advancement in Technology
6. Avantra Biosciences and MedTrust Online Partner to Develop Clinically Important Protein Biomarker Assays for Improving Cancer Care
7. Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration
8. Important Information for Betaseron® (interferon beta 1-b) Consumers Regarding Triad Groups Alcohol Prep Products
9. AVMA Offers Important Guidance to DEA on New Controls for Induction Agent—Propofol
10. Activity Against Key Drug-Resistant Pathogens is the Most Important Attribute Influencing Surveyed Physicians Antibiotic Selection for Nosocomial Pneumonia in the U.S.
11. Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... 20, 2017 Research and Markets has announced ... Driven by Rapidly Expanding Injectables Market and Increasing Usage of Complex ... ... technologies will rise from USD 20 Billion in 2015 to around ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ...
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... ... wear distributors and International relief organizations across the globe to provide effective protection ... lifestyle and work wear collections via insectshield.com . In the wake of ...
(Date:4/23/2017)... ... 2017 , ... Altura Communication Solutions, a nationwide provider of ... and SMB specialization. Altura is now qualified to sell, install and support ... Certification, Altura fulfilled the training and exam requirements for the Cisco Small Medium ...
(Date:4/22/2017)... ... April 22, 2017 , ... Brian Emmer ... President of Sales and Business Development at OAKWORKS, Inc. Mr. Emmer is ... development, and strategic planning for the company. Recognized industry-wide as a healthcare ...
(Date:4/21/2017)... ... April 21, 2017 , ... The staff at Palm Beach Face is proud to announce that ... 2017 London Marathon. Set to take place on April 23rd, the London Marathon has a ... will run as part of team EMPOWER, raising money for the international charity, Smile Train. ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Brady ... announced that its B-595 and B-7569 vinyl label materials received ... and warning labels are tested to remain intact and legible, for use on chemical ...
Breaking Medicine News(10 mins):